VIBES Technology: A Revolutionary Approach in the Fight Against Obesity Epidemic

0
784

The obesity epidemic in the United States presents a significant public health challenge, with nearly 42% of US adults grappling with this condition. This alarming statistic underscores the escalating burden on healthcare systems due to the rise in obesity-related comorbidities such as diabetes, hypertension, cancer, and heart disease.

Traditional methods of weight management, including behavior modification and pharmacological treatments, often fall short in effectively curbing this trend. Bariatric surgeries, such as Roux-en-Y and laparoscopic banding, have shown promise.

However, they demand significant lifestyle changes and are cost-prohibitive, ranging from $7,400 to $34,000, making them inaccessible for many who need them.

The Role of Vagal Nerve Signaling in Weight Management

Central to understanding and potentially managing obesity is the role of the vagal nerve in regulating satiety. The vagal nerve’s intricate signaling mechanism involves anorexigenic neurometabolic secretions in response to food intake, playing a pivotal role in controlling hunger and fullness. This mechanism, primarily volume-dependent rather than composition-dependent, has led to the development of interventions like intragastric balloons (IGBs) to manipulate gastric volume. Despite their initial success in inducing early satiety, IGBs have shown limitations in sustaining long-term changes in eating behavior and have raised safety concerns following several fatalities and FDA warnings.

Alternative Approaches: Vagotomies and Electrical Vagus Nerve Stimulation

Exploring more targeted interventions, researchers have delved into vagotomies and electrical vagus nerve stimulation (VNS). These localized approaches have shown potential in decreasing weight gain and altering food preferences in preclinical studies. Clinical applications of VNS in treating conditions like depression and epilepsy have also indicated positive effects on weight management. However, challenges persist, including non-gastrointestinal side effects and the inability to target specific axons for patterned stimulation, hindering their widespread application for obesity treatment.

Vibrating Ingestible BioElectronic Stimulator (VIBES): A Novel Approach

A groundbreaking development in this field is the Vibrating Ingestible BioElectronic Stimulator (VIBES) pill. This ingestible device is designed to induce illusory distension of the stomach, mimicking the satiety signals generated during food intake. The VIBES pill, through intraluminal mechanical stimulation, aims to achieve early satiety and thus, reduce food intake. In animal models, the VIBES pill has shown promising results in decreasing food intake and slowing weight gain, potentially offering a safe and effective tool for weight management.

Understanding the Mechanism of VIBES

The VIBES pill functions by activating gastric stretch receptors, simulating the stomach’s response to being filled with food. It is designed to be orally ingested, with a mechanism that activates upon contact with gastric fluid, vibrating at amplitudes sufficient to stimulate gastric receptors. The device’s impact on gastric mucosal stroking, hormone secretion related to feeding behavior, and overall gastric motility has been extensively studied, showing promising outcomes in terms of safety, efficacy, and biocompatibility.

Fig. 1. VIBES concept and mechanism.

(A) The Vibrating Ingestible BioElectronic Stimulator (VIBES) makes contact with the gastric lining and activates following contact with gastric fluid. Vibrations activate intraganglionic laminar endings (IGLEs) in the celiac plexus, signaling distension to the NTS, which interacts with hunger circuitry to signal illusory distension. (B) VIBES sits among gastric rugae in a swine stomach and strokes the mucosa as it performs stimulation. (C) The VIBES pill consists of an (1) offset motor, (2) silver oxide battery, (3) central body, (4) motor cap, (5) pill cap, (6) pogo pin, (7) gelatinous membrane, and (8) resistor. Original illustration by V. Fulford.

The Impact of VIBES on Food Intake and Behavior

Clinical trials with the VIBES pill have demonstrated significant reductions in food intake in swine models. Notably, the pill’s effect appears to be transient, with food intake returning to normal levels when the treatment is not administered, indicating the absence of long-term neural adaptation or habituation to the treatment. Behavioral studies further revealed changes in activity levels, correlating with the postprandial state induced by the VIBES treatment.

Safety and Biocompatibility Considerations

The safety and biocompatibility of the VIBES pill have been a primary focus in its development. Studies have shown no significant adverse effects on the gastric lining, motility, or overall health status in animal models. Furthermore, the device does not significantly alter gastric pH levels or trigger distress symptoms like nausea or vomiting, which are often associated with excessive activation of certain gastric

DISCUSSION

Luminal Vibratory Stimulation and Gastric Stretch Receptor Activation

This study successfully established a novel approach using the VIBES technology, which utilizes luminal vibratory stimulation to activate gastric stretch receptors. This activation effectively signals distension and initiates the gastric phase of satiety. By fine-tuning the vibrational frequencies and enhancing mucosal interactions, the VIBES pill not only triggers vagal afferent signals indicative of stomach distention but also consistently reduces food intake in animal models. This approach aligns with the well-established and sustainable principle of limiting caloric intake to control weight gain. The proposed method of ingesting the VIBES pill before meals could efficiently evoke early satiety, potentially transforming mealtime experiences and calorie consumption patterns.

Advantages of VIBES Technology

The VIBES pill, as an ingestible device, offers several distinct advantages over existing weight management interventions. Its non-invasive nature eliminates the need for surgical procedures, allowing for direct stimulation within the gastric cavity. The anticipated low production cost due to scalable manufacturing processes positions VIBES as an affordable and consumable option. Additionally, the possibility of developing implantable or gastric-resident versions of the device could cater to patients requiring long-term therapy, reducing the need for frequent oral administration.

Practical Considerations and Design Efficiency

The design of the VIBES pill accounts for practical challenges associated with oral administration. Its effective function within a specific frequency range ensures its efficacy amidst varying gastric conditions. The pill’s ability to consistently evoke a stretch response, despite its uncontrolled positioning in the stomach, is a critical feature, supported by the slow-adapting nature of gastric tension receptors. The large animal study underscores the consistency of the VIBES treatment in reducing food intake without causing distress, side effects, or passage issues, affirming its safety and effectiveness in a relevant model.

Future Directions and Clinical Implications

Future research should focus on miniaturizing the VIBES device for broader applicability and exploring its efficacy in models with stomach geometries more akin to humans. Investigating the VIBES pill’s impact on nutrient absorption, microbiome changes, and overall GI tract functionality will be crucial. Enhancing control over the pill’s activation/deactivation could increase its safety and convenience for users.

Clinically, the VIBES technology holds potential to revolutionize treatment options for obesity-related disorders, including polyphagia and Prader-Willi syndrome, where delayed satiety leads to overeating and associated health issues. Comparisons with existing FDA-approved weight control drugs and emerging techniques like electrical stimulation will be vital in establishing the VIBES pill’s position in the therapeutic landscape. Additionally, its potential in managing conditions like type II diabetes, through its impact on insulin regulation, warrants further exploration. The VIBES pill’s role in enhancing GI motility and the possibility of leveraging optogenetic activation of mechanoreceptors represent exciting areas for future research.

In summary, this study lays a critical foundation for a vibratory modality of vagal stimulation, utilizing gastric mechanoreceptors to induce an illusory sense of satiety. This approach opens new avenues for managing obesity, emphasizing the reduction of food intake and the control of weight gain, and heralds a new era in obesity treatment strategies.


reference link : https://www.science.org/doi/10.1126/sciadv.adj3003

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.